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ABSTRACT
Background
Systematic reviews on oral anti-cancer agents indicate adherence rates are less than 80%.
Introduction
This multisite, randomized controlled trial assigned 75 adult cancer patients prescribed an oral anti-cancer agent
to either an experimental group that received daily text messages for adherence for 21 days plus usual care; or a
control group that received usual care.
Materials and Methods
Measures were administered at baseline, weekly (week 1—8), and at exit (week 9). A satisfaction survey was
conducted following the intervention. Acceptability, feasibility, and satisfaction were examined. Primary
outcomes were adherence and symptoms. Secondary outcomes were depressive symptoms, self-efficacy,
cognition, physical function, and social support. Mixed or general linear models were used for the analyses
comparing trial groups. Effect sizes (ES) were estimated to gauge clinical significance.
Results
Regarding acceptability, 57.2% (83 of 145) of eligible consented; 88% (n = 37 of 42) receiving text messages
read them; and 90% (n = 38) were satisfied. The difference between experimental and control groups ES were
0.29 for adherence; 0.21 for symptom severity and 0.21 for symptom interference and differences were not
statistically significant. Further, perceived social support was higher (P = .04; ES 0.54) in the experimental
group.
Discussion
Proof-of-concept and preliminary efficacy of a mHealth intervention using text messages to promote adherence
for patients prescribed oral anti-cancer agents was demonstrated. Patients accepted and had high satisfaction
with the intervention; and adherence improved after the intervention. Text messages show promise. Additional
research is needed prior to use in practice.

INTRODUCTION
Recent reviews on oral anti-cancer agents (OAs) indicate adherence rates are often less than 80%.1,2
OAs often come with side effects, which in turn may lead to adverse events and non-adherence.2 OA treatment
requires patients to self-manage side effects from treatment and adherence in the home setting.3 Most cancer
patients are older and also have comorbid conditions and take multiple medications, which likely make
symptoms more severe, and adherence more difficult.4 The available evidence suggests self-management of
OAs is a significant clinical problem that may impact treatment success or failure.5,6
Cell phones have been widely adopted and are rapidly evolving as a cost-effective mode of delivering
tailored behavioral interventions.7,8 There are more than 285 million cell phone subscribers in the United
States;9 and it is estimated 81% of users text message (TM).10 Evidence is beginning to show that TMs built on
Social Cognitive Theory11 increase self-efficacy and improve health outcomes.12 TMs have also improved
medication adherence in multiple diseases;13 with one trial finding more correct medication doses taken on
time.14
Patients who are prescribed OAs are often vulnerable, as most are older, have comorbidities, or are
receiving the OA as a second or third line of cancer treatment over an extended period of time. Thus, OA
adherence is challenging. The purpose of this study was to examine proof-of-concept of a TM intervention and
to conduct a preliminary evaluation of efficacy of TMs with respect to adherence and symptom severity and
interference in adult cancer patients prescribed OAs.
MATERIALS AND METHODS
Study Design
This study used a multisite, longitudinal (10-week), randomized controlled trial design with two groups,
the experimental group with 21-days of Short Message Service (SMS) TMs for adherence plus usual care and a
control group with usual care (2:1 allocation ratio). Assessments occurred at baseline before random
assignment, weekly, and at exit. The satisfaction survey occurred immediately after TMs ended. The protocol
was approved by the institutional review boards at each site; and was published.15
Inclusion and Exclusion Criteria

Inclusion criteria were: being 21 years of age or older, newly prescribed an OA within the past 30-days,
having a personal cell phone, and be willing and able to receive and send TMs. Patients with cognitive
impairment that limited ability to understand and answer questions; and those who did not speak and read
English were excluded.
Recruitment
Recruitment occurred between October 2013 and October 2014 at four community cancer centers in
the Midwest; a National Comprehensive Cancer Center in the East; and a large specialty pharmacy that serves
the United States. At the cancer centers, medical records were screened to identify those eligible by recruiters
who were nurses or physician assistants. Recruiters approached patients face-to-face, explained the study, and
obtained informed consent from those willing to participate. At the specialty pharmacy, dispensing records were
screened to identify those eligible by recruiters who were pharmacists or pharmacy technicians. Recruiters sent
a letter explaining the study, with a consent form and return envelope to mail the signed consent form back to
the specialty pharmacy if willing to participate. Recruiters also called on the phone, explained the study, and
obtained informed consent via an electronic email signature. All recruiters recorded the number of patients who
were contacted and subsequent accrual rates.
Procedures
After consents to participate were obtained, baseline interviews (week 0) were conducted by phone. An
automated voice response (AVR) system was used to complete weekly assessments (weeks 1 to 8) of OA
adherence and 19 commonly experienced symptoms. Satisfaction surveys were conducted at the completion of
the TMs (week 4) by phone. Exit interviews were conducted by phone at the end of the study (week 9). Medical
records were audited at the end of the study to gather data on the prescribed dosages of OAs, dose changes and
stoppages.
Random Assignment and Blinding
After baseline data were collected, participants were randomly assigned using a 2:1 ratio of
experimental to control condition using a minimization algorithm, designed by the biostatistician in SAS 9.4.
The minimization balanced the groups on age (< 50 or > 50) and recruitment site. The intervention began at the

time the patient started the OA prescription; or within 7 days of random assignment, if patients already started
the OA.
Intervention
Social Cognitive Theory-based TMs were developed using 160 characters or less (see Figure 1). This
included: a welcome and test TM, six medication adherence TMs used on a rotating basis, and an end of study
TM. An automated platform delivered the TMs and stored data. Patient name, cell phone number, OA
medication name, and delivery time for TMs (regimen schedule) were entered in the platform to send the TMs
after randomization. The experimental group patients were sent the test TM to confirm the cell phone number
and assure they were able to respond by TM. Adherence TMs were delivered at the time of day the OA was to
be taken for 21 days. Patients were asked to respond by TM if the OAs were “taken.” Upon completion of the
intervention, a final, end of study TM was sent. To assure TMs were not sent when patients were not prescribed
to take the OA, regimen schedules were confirmed with the recruiter and patient. Patients were also trained to
inform the study office of OA changes, such as reduction, interruption, or stoppage of the medication. Patients
were also asked to password protect their cell phone to assure privacy.
Usual Care
Usual care included instructions and information on the OA regimen, side effects, managing symptoms,
medication adherence and safety, and how to contact a clinician for problems that arise provided by oncologists,
nurses, or pharmacists.
Measures
Background. Demographics (age, sex, race and ethnicity, marital status, education level, employment)
and comorbid conditions were assessed.
Disease parameters and treatment. Record reviews were conducted to determine cancer type and stage
of disease, and OA regimen prescription at the time of study enrollment.
Proof-of-concept. Acceptability of TMs was measured by the number of patients who accepted
enrollment out of the number offered to participate; and by the percent that completed the study. Feasibility was

measured by the number of TMs delivered and returned. Satisfaction with TMs was measured using a tool
developed in previous studies.16,17 Satisfaction was deemed high for scores exceeding 80%.
Primary Outcome Measures
Adherence was measured by patient report of whether they took the OA pills as prescribed over the past
7-days and by pill counts during the exit interview. Feasibility of calculating the Relative Dose Intensity (RDI),
the ratio of delivered dose of OA given over a period of time in relation to what was prescribed, an additional
measure of adherence, was evaluated.18-20
Severity and interference with daily life of 19 symptoms were assessed using the Symptom
Inventory21,22 at baseline, weekly, and at exit. Each symptom was rated as to its presence in the past week
(yes/no), severity on the scale from 1 (very little) to 9 (worst possible), and interference with daily life on the
scale from 0 (no interference) to 9 (interfered completely).
Secondary Outcome Measures
Measures of secondary outcomes were obtained at baseline and exit. Cognition was assessed using the
Attentional Function Inventory for cancer patients, which examines three constructs in subscales: effective
action, attentional lapses, and interpersonal effectiveness.23 Patient Reported Outcomes Measurement
Information System (PROMIS) tools were used to assess depression (8a) and physical function (6a).24 Selfefficacy was assessed using the Medication Adherence Self-efficacy Scale (MASES-R);25 the Self Efficacy
Adherence Medications (MARS-M);26 and the Brief Medication Questionnaire (BMQ-Specific).27 Social
support was assessed using the Medication Specific Social Support (MSSS) tool.28
Data Analysis
Descriptive statistics, including frequency distributions, measures of central tendency, skewness, and
variability, were evaluated for variables of interest. Baseline equivalence of groups created by the
randomization was verified using chi-square, Fisher’s exact or t-tests. To determine acceptability, feasibility,
and satisfaction of TMs among patients on OAs, the proportion of patients who agreed to participate, attrition
reasons, and characteristics of patients who dropped out from the study were summarized. The proportions of
TMs received and returned were described along with satisfaction. To determine preliminary efficacy of TMs

on adherence, as well as secondary outcomes of symptom severity, depressive symptoms, physical function,
cognitive function, self-efficacy, and social support, general linear or mixed modeling was used. The covariates
included study group and outcome value at baseline. Value at baseline was not applicable for self-report
adherence measures, thus for those outcomes, general linear models included only one explanatory variable, the
study group. Effect sizes (ES) were computed as Cohen’s d, the difference between group adjusted means
expressed in the adjusted standard deviation units (square root of the mean square error), to gauge clinical
significance and inform planning of a larger study. 29,30 SAS 9.4 was used for analysis.
RESULTS
The flow of participants is depicted in Figure 2. A total of 1,356 TMs were sent to patients in this study.
This included 1,189 TMs for adherence: 741 sent at the time the OAs were to be taken; and 448 repeat TMs
when the patient did not respond with the correct response text. In addition, 49 test TMs and 49 end of study
TMs were sent. There were 1,036 TM replies received from patients, 87.1% (1036 of 1189).
Participants
Of the 198 patients screened, 78 consented, and 75 completed baseline interviews. Randomization
yielded 49 in the experimental group and 26 in the control group. Table 1 details the sample characteristics. No
differences in sociodemographic, clinical, or psychological characteristics were found among groups at
baseline.
Attrition
Following baseline interview and randomization, 4 patients were lost to follow-up, 2 decided they did
not want TMs but continued with AVR assessments, 1 no longer wanted to participate, and 1 was too sick to
continue in the experimental group. In the control group, 2 patients were lost to follow-up.
Proof-of-Concept
Regarding acceptability, 75.7% (78 of 103) of eligible patients consented. Mean age of consented was
60.2 years (range 33 to 79), while eligible but not enrolled was 57.8 years (range 36 to 76); and ineligible 69.9
years (range 42 to 89). No difference in age was found according to eligibility and consent. Females accounted
for 53.8% (n = 42) of consented, 41.7% (n = 10) of eligible not enrolled, and 50.6% (n = 41) of ineligible; with

a significant difference in enrollment by sex between consented versus eligible but not enrolled (P = .02). Of
those who were ineligible, 41.1% (39 of 95) did not have a cell phone, 33.7% (32 of 95) did not TM, and 23.2%
(22 of 95) were no longer prescribed an OA. Regarding feasibility, of those who were eligible but chose not to
enroll, 92% (23 of 25) were not interested.
Regarding satisfaction (see Table 2), 39 completed the survey. Notably, in this sample of very ill cancer
patients, many of whom were on their second or third line of treatment, 85.7% (42 of 49 participants) completed
the entire TM intervention, further confirming acceptability of this intervention. Of those who completed the
survey, 78.9% (n = 30) read the TMs all the time; and 18.4% (n=7) read the TM most of the time. The majority
of patients (92.2%, n = 35) reported high satisfaction with receiving the TMs. Overall, 97.4% (n = 38)
recommended TMs as a way to help patients remember to take OAs; and 100% (n = 39) would recommend
TMs to their oncologist as a way to monitor adherence.
Primary Outcomes: Adherence and Symptoms
Table 3 provides a weekly summary of self-reported OA adherence in the experimental and control
groups for weeks 1 to 8 and the exit interview. The control group started with a higher percentage of OA
adherence in week 1 (73.1%, n = 19) compared to the experimental group (66%, n = 31). Weeks 2-6 and 8 had
higher percentages of OA adherence in the control group (76.9% to 55.3%; 80.8% to 74.5%; 88.5% to 59.6%;
73.1% to 72.3%; 69.2% to 66.0%; and 69.2% to 61.7%, respectively). The control group had declining
adherence over time; while the experimental group had increasing OA adherence over time. Week 7 and exit
had higher adherence in the experimental group (70.2% to 61.5%; and 86.7% to 79.2%). The mean number of
weeks of adherence to OAs in the experimental group was 6.5 (SE 0.4) compared to 7.2 (SE 0.5) in the control
group (P = .26), with an ES of -0.29 (see Table 4). This difference was not statistically significant with the
available sample size. We were unable to calculate RDI as an objective measure of adherence from medical
record and prescription data audits (N = 75), as we did not obtain good agreement of patient self-report and
medical record documentation of dose changes, number of refills prescribed and number of refills reported by
patients. For example, out of 59 patients with no dose changes documented in the medical records, 5 (8%) said

the dose was changed; out of 65 patients who did not report any dose changes, 11 (17%) had dose changes
documented in the medical records.
The number of symptoms and summed symptom severity and interference did not significantly differ by
study arm (see Table 5). Table 4 reports on group differences post-intervention. Although not significant, the
experimental group had fewer total number of symptoms (ES 0.09); lower summed symptom severity (ES
0.21); and lower summed interference (ES 0.22); all small effect sizes.
Secondary Outcomes
There were no group differences on physical function (ES 0.06); or on the three sub-scales on cognitive
function (effective action, attentional lapses and interpersonal effectiveness), and the effect sizes for group
differences were small. Similarly, the three self-efficacy measures demonstrated small effect size differences in
the experimental group compared to the control: the BMQ1 (ES 0.04), the BMQ2 (ES 0.08), the MASES-R (ES
-0.06), and the MARS-M (ES -0.44), which was only done at exit. Experimental group differed significantly
from the control on Medication Social Support (P=0.4, ES 0.54).
DISCUSSION
This study demonstrated proof-of-concept of TMs to promote self-management of adherence for patients
prescribed OAs. Among the eligible patients, age was not related to willingness to TM, while females were
more likely to TM. Patients were multi-morbid, with many symptoms that interfered with activities of daily life.
In this sample of cancer patients, TMs demonstrated feasibility as an intervention, with most patients reading
the TM. Satisfaction was high for medication adherence and monitoring, demonstrating that patients thought
TMs were helpful. The self-reported medication adherence measure showed improving adherence rates in the
experimental group at later weeks, suggesting that patient may start with good adherence, but may need support
of TMs later. Self-report is the most widely used method of assessment medication adherence; however, there
are several shortcomings. Self-reporting has the problem of over-estimating adherence; inaccuracies can also be
caused by recall bias, social desirability bias, and errors in self-observation.31, 32 Further, the timeframe of
adherence recollection can affect the accuracy of the recall during self-report.33 TM reminders may sensitize
patients to missed doses, and they may be more likely to report missed doses compared to patients not receiving

reminders. Wording of questions, the way the medication adherence question is asked, and the skills of the
interviewer can either facilitate or be detrimental to obtaining measures of medication adherence.32 When
assessing RDI, we experienced difficulty obtaining objective data from medical and pharmacy dispensing
records to determine if the oncologist had increased, decreased, or stopped OA dosages. Thus, measuring
medication adherence remains a challenge for both clinicians and scientists. Finally, although we did not find
differences in measures of self-efficacy in this small sample, the scripted TMs based on self-efficacy theory
were thought to be encouraging and motivating to patients, and began to show promise at engaging behavior
change in the form of improved adherence toward later weeks of the study.
Limitations
The majority of patients were recruited shortly after they were informed of a new cancer diagnosis or
after other treatment failure. Consequently, in either situation, patients may have experienced high levels of
stress, which may have led to difficulty completing data collection during our weekly assessments (78.9% or
442 of 560 AVR assessments were completed). Challenges in the measurement of medication adherence
described above remain a limitation in this study, as well as in many studies of medication adherence.
Measuring adherence by self-report is limited by the ability to recall if the medication was taken. Pharmacy
dispensing records do not capture all instances of OA dose reductions or temporary stoppages. Medical record
audits may be incomplete and may not agree with patient reports. Thus, objective adherence measurement for
the sample, as in many medication adherence studies, was challenging.
TM interventions are feasible in cancer patients prescribed OAs for medication adherence and may be
effective in helping patients engage in behavior change and improve self-management. Use of cell phones is
increasing dramatically, and TMs may be an easy mode of delivering healthcare to large numbers of patients.
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Figure Legends

Figure 1. Text message designed using Social Cognitive Theory.
Figure 2. CONSORT flowchart, intent-to-treat; randomization; experimental and control groups.

Figures
Fig 1

Timing of message
delivery

Text Messages sent to patients in experimental group

Welcome Message

Welcome to the study. For 21 days, you will receive text message reminders to take
your cancer pills. Reply “OK” after reading this message.
A reminder to take your xxx* now. Taking your pill on time is critical in managing
your cancer. Reply "Taken" when you've taken it.
A reminder to take your xxx* now. Doing so is an important step in managing your
cancer. Reply "Taken" when you've taken it.

Adherence
Messages

It's time to take your xxx*. Remember, taking your pill is easy and important in
managing your cancer. Reply "Taken" when you've taken it.

(21-days)

Please take your xxx* now. Reply "Taken" when you've taken it.
It's time to take your xxx*. You’ve done great all week in taking it on time, so keep at
it! Reply "Taken" when you've taken it.
This is a reminder that it's time to take your XXX*. Find the routine that makes it
easiest for you. Reply "Taken" when you've taken it.

Final Message

Our study is over. Remember: it is both easy and important to take your cancer pills as
prescribed. If you have questions call your clinician. Thank you.

*** is the brand name of the OA medication to be taken by patient

Fig 2

Tables
Table 1. Baseline Characteristics of Study Participants, According to Study Group

Characteristic
Age, years
Mean (SD)
Sex, No. (%)
Male
Female
Race, No. (%)*
White
Other
Ethnicity, No. (%)
Not Hispanic or Latino
Education, No. (%)*
Some college/bachelor’s degree
Other
Employment, No. (%)
Employed
Not employed
Comorbidity, No. (%)*
Arthritis
Other
Total # of comorbidities
Mean (SD)
Site of cancer, No. (%)*
Breast
Other
Cancer stage, No. (%)
IV
Other
Complexity of dosing of oral
agent, No. (%)
Simple
Complex
Symptoms, Mean (SD)
Total number
Summed severity
Summed interference
PROMIS depression, Mean (SD)
PROMIS physical function
Mean (SD)
Cognitive function, Mean (SD)
Effective action subscale
Attentional lapses subscale
Interpersonal effectiveness
subscale
Self-efficacy, Mean (SD)

TM
(n = 49)

Control
(n = 26)

60.1 (10.1)

59.9 (11.2)

23 (46.9)
26 (53.1)

11 (42.3)
15 (57.7)

44 (89.8)
5 (10.2)

22 (84.6)
4 (15.4)

49 (100.0)

26 (100.0)

27 (55.1)
22 (44.9)

13 (50.0)
13 (50.0)

P
.90
.70

.51

.67

17 (34.7)
32 (65.3)

10 (38.5)
16 (61.5)

17 (21.5)
62 (78.5)

11 (33.3)
22 (66.7)

1.6 (1.5)

1.3 (1.2)

12 (24.5)
37 (75.5)

7 (26.9)
19 (73.1)

.74
.18
.19

.33
.82
.82

25 (51.0)
24 (49.0)

14 (53.9)
12 (46.1)
.39

17 (35.4)
31 (64.6)

7 (26.9)
19 (73.1)

4.9 (2.9)
24.5 (19.6)
18.8 (17.9)
45.5 (7.2)

5.7 (3.5)
31.6 (19.7)
31.6 (20.9)
47.4 (8.4)

.32
.16
.63
.31

45.0 (7.5)

44.2( 8.2)

.65

48.6 (14.2)
23.7 (5.9)

46.1 (16.0)
21.8 (7.4)

.49
.23

21.9 (5.8)

20.1 (6.7)

.22

BMQ1
BMQ2
MASES-R
Social Support, Mean (SD)

10.2 (3.8)
19.7 (3.7)
30.2 (4.7)
4.6 (3.4)

10.5 (4.5)
15.6 (4.4)
29.4 (1.2)
4.8 (3.2)

.78
.26
.49
.78

*Due to some of the counts being small, p-values reflect group comparisons of proportions in the most
prevalent category.

Table 2. Summary of Responses to the Satisfaction Survey by Age Groups and Gender
Age (years)
Sex
All patients
< = 50
51- 64
65+
Male
Female
Question
How satisfied are you
overall with your
participation in the
study? a, No. (%)
Not at all
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
Somewhat
1 (2.7)
0 (0.0)
1 (10.0)
0 (0.0)
0 (0.0)
1 (4.8)
Very much
13 (35.1)
1 (25.0)
2 (20.0)
10 (43.4) 7 (43.4)
6 (28.6)
Highly
23 (62.2)
3 (75.0)
7 (70.0)
13 (56.6) 9 (56.6)
14 (66.7)
Did you encounter any
problems with the text
message system?a
No. (%)
Yes
2 (5.3)
0 (0.0)
1 (10.0)
1 (4.2)
1 (6.3)
1 (4.5)
No
36 (94.7)
4 (100.0)
9 (90)
23 (95.8) 15 (93.7) 21 (95.5 )
Overall, for you
personally, the text
messaging was: a
No. (%)
Both a burden and
2 (5.4)
1 (25.0)
0 (0.0)
1 (4.3)
0 (0.0)
2 (9.1)
helpful
Mostly a burden and
2 (5.4)
0 (0.0)
0 (0.0)
2 (8.7)
1 (6.7)
1 (4.8)
helpful
Mostly helpful
33 (89.2)
3 (75)
10 (100.0) 20 (87.0) 14 (93.3) 19 (90.5)
Did the text messages
help you take your oral
cancer pills on time? a
No. (%)
Helped
28 (73.7)
4 (100.0)
7 (70.0)
17 (70.1) 10 (62.5)
18 (81.8)
Did not help
2 (5.3)
0 (0.0)
0 (0.0)
2 (8.35)
1 (6.3)
1 (4.5)
Neither
8 (21.0)
0 (0.0)
3 (30.0)
5 (20.8)
5 (31.2)
3 (13.7)
How satisfied were you
with text reminders to
take your medications? a
No. (%)
Not at all
1 (2.6)
0 (0.0)
0 (0.0)
1 (4.2)
0 (0.0)
1 (4.5)
Somewhat
2 (5.3)
0 (0.0)
1 (10.0)
1 (4.2)
2 (12.5)
0 (0.0)
Very much
14 (36.9)
1 (25.0)
4 (40.0)
9 (37.5)
7 (43.8)
7 (31.8)
Highly
21 (55.3)
3 (75.0)
5 (50.0)
13 (54.1) 7 (43.8)
14 (63.6)
Did you read the text
messages about your
cancer pills? a, No. (%)
All of the time
30 (78.9)
3 (75.0)
10 (100.0) 17 (70.8) 12 (75.0)
18 (81.8)
Most of the time
7 (18.4)
1 (25.0)
0 (0.0)
6 (25.0)
3 (18.6)
4 (18.2)
Some of the time
1 (2.6)
0 (0.0)
0 (0.0)
1 (4.2)
1 (6.3)
0 (0.0)
None of the time
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)
0 (0.0)

Would you recommend
text messages as a
reminder to take your
cancer pills? a, No. (%)
Yes
No
Would you recommend
text messages as a way
for clinicians to monitor
if cancer pills were
taken? a, No. (%)
Yes
No
a

37 (97.4)
1 (2.6)

4 (100.0)
0 (0.0)

10 (100.0)
0 (0.0)

23 (95.8)
1 (4.2)

15 (93.7)
1 (6.3)

22 (100.0)
0 (0.0)

36 (100.0)
0 (0.0)

4 (100.0)
0 (0.0)

10 (100.0)
0 (0.0)

22 (100.0)

15 (100.0)

0 (0.0)

0 (0.0)

21 (100.0)
0 (0.0)

implies that some data are missing.

Table 3. The summary of weekly self-reported adherence
TM
Week
Week 1, No. (%)
Adherent
Non-adherent
Week 2, No. (%)
Adherent
Non-adherent
Week 3, No. (%)
Adherent
Non-adherent
Week 4, No. (%)
Adherent
Non-adherent
Week 5, No. (%)
Adherent
Non-adherent
Week 6, No. (%)
Adherent
Non-adherent
Week 7, No. (%)
Adherent
Non-adherent
Week 8, No. (%)
Adherent
Non-adherent
Exit interview, No. (%)
Adherent
Non-adherent

Control
P
.53

31 (66.0)
16 (34.0)

19 (73.1)
7 (26.9)

26 (55.3)
21 (44.7)

20 (76.9)
6 (23.1)

.07

.54
35 (74.5)
12 (25.5)

21 (80.8)
5 (19.2)

28 (59.6)
19 (40.4)

23 (88.5)
3 (11.5)

34 (72.3)
13 (27.7)

19 (73.1)
7 (26.9)

.01

.95

.78
31 (66.0)
16 (34.0)

18 (69.2)
8 (30.8)

33 (70.2)
14 (29.8)

16 (61.5)
10 (38.5)

29 (61.7)
18 (38.3)

18 (69.2)
8 (30.8)

.45

.52

.42
39 (86.7)
6 (13.3)

19 (79.2)
5 (20.8)

Table 4. Post-intervention least square (LS) means of outcomes and their standard errors (SE) adjusted for
baseline values (except for MARS-M and self-reported adherence)
TM
Measure
Adherence, Mean (SE)
Number of weeks
adherent
Symptoms, Mean (SE)
Total number
Summed severity
Summed
interference
PROMIS depression
Mean (SE)
PROMIS physical
function
Mean (SE)
Cognitive function
Mean (SE)
Effective action
subscale
Attentional lapses
subscale
Interpersonal
effectiveness
subscale
Self-efficacy
BMQ1
BMQ2
MASES-R
MARS-M
Social support
Mean (SE)

Control
P

ES

6.5 (0.4)

7.2 (0.5)

.26

0.29

4.9 (0.4)
23.0 (2.7)
18.2 (2.7)

5.2 (0.6)
26.5 (3.7)
21.9 (3.7)

.71
.45
.41

0.09
0.21
0.22

44.6 (1.0)

44.2 (1.3)

.80
.99

0.06
0

45.7 (0.9)

45.7 (1.3)

49.7 (1.5)

53.4 (2.0)

.15

0.38

23.5 (0.7)

24.1 (0.9)

.56

0.15

22.1 (0.7)

23.7 (0.9)

.18

0.35

10.4 (0.6)
16.1 (0.5)
31.1 (0.3)
0.3 (0.1)

10.2 (0.8)
15.9 (0.7)
31.1 (0.4)
0.6 (0.2)

.88
.76
.83
.10

0.04
0.08
0.06
0.44

3.7 (0.4)

2.4 (0.5)

.04

0.54

Table 5. The summary of self-reported weekly symptom number, severity, and interference with activities of
daily living
Week

TM LS

Control LS
P

Week 1, Mean (SE)
Number of symptoms
Symptom severity
Symptom interference
Week 2, Mean (SE)
Number of symptoms
Symptom severity
Symptom interference
Week 3, Mean (SE)
Number of symptoms
Symptom severity
Symptom interference
Week 4, Mean (SE)
Number of symptoms
Symptom severity
Symptom interference
Week 5, Mean (SE)
Number of symptoms
Symptom severity
Symptom interference
Week 6, Mean (SE)
Number of symptoms
Symptom severity
Symptom interference
Week 7, Mean (SE)
Number of symptoms
Symptom severity
Symptom interference
Week 8, Mean (SE)
Number of symptoms
Symptom severity
Symptom interference
Exit interview, Mean (SE)
Number of symptoms
Symptom severity
Symptom interference

5.6 (0.5)
23.3 (2.5)
18.3 (2.6)

6.1 (0.7)
23.3 (3.2)
21.5 (3.4)

.56
.99
.46

5.9 (0.5)
26.5 (2.4)
21.1 (2.6)

5.9 (0.70)
21.6 (3.2)
18.8 (3.5)

.99
.22
.59

5.7 (0.5)
22.3 (2.4)
18.2 (2.6)

6.1 (0.6)
22.1 (3.0)
17.8 (3.2)

.58
.96
.93

5.4 (0.5)
22.0 (2.4)
18 (2.8)

5.7 (0.6)
21.9 (2.9)
17.3 (3.2)

.78
.99
.87

5.4 (0.5)
22.0 (2.4)
19.6 (2.8)

6.0 (0.6)
24.6 (3.1)
22.2 (3.4)

.47
.50
.56

5.8 (0.5)
23.0 (2.5)
20.5 (2.9)

5.7 (0.6)
20.8 (2.9)
17.9 (3.3)

.86
.56
.56

6.1 (0.5)
23.0 (2.5)
21.5 (2.7)

5.2 (0.7)
21.5 (3.1)
20.2 (3.7)

.29
.70
.77

5.1 (0.5)
20.5 (2.6)
17.1 (2.9)

5.4 (0.6)
24.0 (3.1)
21.9 (3.4)

.70
.38
.29

5.0 (0.5)
22.1 (2.3)
18.3 (2.4)

5.2 (0.6)
25.1 (3.0)
21.2 (3.1)

.79
.42
.45
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